Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576847 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
A Phase 3 study of Rosacea, sponsored by Maruho Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 307
- Enrollment target
- 20
- Study locations
NCT02576847 is a Phase 3 study of Rosacea that has completed, run by Maruho Co.. The registered enrollment target is 307 participants, above the 230-participant average among 23 other Rosacea trials with a reported enrollment target (33% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT02576847, a Phase 3 study of Rosacea, has completed, sponsored by Maruho Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 307 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the long-term safety of once-daily application of Omiganan topical gel in subjects with severe papulopustular rosacea.
Conditions Studied
Interventions
- DRUG Omiganan
Study Locations (20)
Florida
- - Miami
- - Miramar
- - Tampa
Indiana
- - Carmel
- - Indianapolis
- - Plainfield
Texas
- - Dallas
- - Pflugerville
- - Webster
California
- - Fremont
Illinois
- - Arlington Heights
Massachusetts
- - Watertown
New Mexico
- - Albuquerque
New York
- - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-02-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02576847
The ClinicalTrials.gov registry entry for NCT02576847 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 307 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 230-participant average among 23 other Rosacea trials with a reported enrollment target (33% higher). The listed sponsor is Maruho Co., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 1 intervention - of which Omiganan is the first listed.
NCT02576847 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Indiana, Texas.
Frequently Asked Questions
What is clinical trial NCT02576847 about?
NCT02576847 is a clinical study titled "Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel". This study evaluates the long-term safety of once-daily application of Omiganan topical gel in subjects with severe papulopustular rosacea.
What is the current status of trial NCT02576847?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 307 participants. The study started on 2015-10. Estimated completion is 2018-02-08.
What conditions does trial NCT02576847 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT02576847?
The interventions under investigation include: Omiganan (DRUG).
Who is sponsoring clinical trial NCT02576847?
This trial is sponsored by Maruho Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02576847 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
COMPLETED · Phase 3
-
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 3
-
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
COMPLETED · Phase 3
-
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 3
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.